In a study reported in the Journal of Clinical Oncology, Arjun Sahgal, MD, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the occurrence of vertebral compression fractures in patients undergoing spinal stereotactic body radiotherapy. Vertebral compression fracture ...
Subcutaneous trastuzumab (not available in the United States) has been shown to have noninferior efficacy and similar pharmacokinetic and safety profiles compared with intravenous trastuzumab (Herceptin) in patients with early-stage HER2-positive breast cancer. In the PrefHer trial reported in...
In the noninferiority ICOGEN trial reported in Lancet Oncology, Yuankai Shi, MD, of the Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs. Beijing, and colleagues compared the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor icotinib with gefitinib...
CNS-directed chemotherapy and cranial radiation therapy for childhood acute lymphoblastic leukemia or lymphoma have neurotoxic effects. In a study reported in Journal of Clinical Oncology, Ilse Schuitema, MSc, of Leiden University, The Netherlands, and colleagues evaluated white matter changes ...
The primary analysis of the Japanese JGOG 3016 trial showed that dose-dense paclitaxel plus carboplatin significantly improved progression-free and overall survival compared with conventional paclitaxel/carboplatin as first-line treatment in patients with advanced ovarian cancer. In a long-term...
Studies evaluating two standards of care in adults with advanced Hodgkin lymphoma—ie, increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine (Matulane), and prednisone (BEACOPPescalated) and doxorubicin, bleomycin, vinblastine, and dacarbazine...
Annual screening for breast cancer with magnetic resonance imaging (MRI) has been found to be cost-effective in women aged 30 to 60 years who are BRCA1 or BRCA2 carriers or who have a 50% chance of being a carrier, and such screening is recommended in these women by many authorities. It is unclear...
It is estimated that 30% to 90% of cancer patients experience impairment of sleep quality post-treatment and such impairment can be severe enough to increase morbidity and mortality. Preliminary evidence indicates that yoga may improve sleep in cancer patients. In a study reported in the Journal of ...
In a study reported in the Journal of the National Cancer Institute, Hannah Arem, MHS, PhD, of the National Institutes of Health, and colleagues analyzed the association between quality of diet according to the 2005 Dietary Guidelines for Americans—Healthy Eating Index 2005...
Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. As reported in Journal of Clinical Oncology by Sandra M. Swain, MD, FACP, of Washington Cancer Institute–MedStar Washington Hospital Center, and colleagues,...
Some data support an association between circadian disruption and prostate cancer. In a study reported in Journal of the National Cancer Institute, Erin E. Flynn-Evans, PhD, of the Division of Sleep Medicine at Brigham and Women’s Hospital, and colleagues assessed the association between...
In a study (Medical Research Council AML 15 Trial) reported in Journal of Clinical Oncology, Alan K. Burnett, MD, of Cardiff University School of Medicine and colleagues compared induction with daunorubicin/cytarabine, daunorubicin/cytarabine plus etoposide, and fludarabine/cytarabine/granulocyte...
In a phase III study (REGAL trial) reported in Journal of Clinical Oncology, Tracy T. Batchelor, MD, MPH, of Massachusetts General Hospital, and colleagues compared oral monotherapy with the pan-VEGF tyrosine kinase inhibitor cediranib and the combination of cediranib plus lomustine (CeeNu) vs...
In a study reported in Journal of Clinical Oncology, Tomasz Huzarski, MD, PhD, of Pomeranian Medical University, Szczecin, Poland, and colleagues from the Polish Hereditary Breast Cancer Consortium assessed survival among women with early-onset breast cancer with and without BRCA1 mutation and...
In a study reported in Journal of Clinical Oncology, Anthony V. Moorman, PhD, of Newcastle University, and colleagues compared outcomes in children and adolescents with B-cell precursor acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21) in a trial in...
Intrachromosomal amplification of a region of chromosome 21 (iAMP21; three or more extra copies of RUNX1 on an abnormal chromosome 21) is a recently identified recurrent genomic abnormality associated with poorer outcome in acute lymphoblastic leukemia (ALL). In a study reported in Journal of...
In the Prostate Cancer Prevention Trial (PCPT), initially reported in 2003, finasteride significantly reduced the risk of prostate cancer by 24.8% but was associated with a relative 26.9% increase in risk of high-grade disease compared with placebo. In a study reported in The New England Journal of ...
In a study (the BEATRICE trial) reported in Lancet Oncology, David Cameron, MD, of the University of Edinburgh, and colleagues evaluated the strategy of adding the antiangiogenic agent bevacizumab (Avastin) to adjuvant chemotherapy in women with triple-negative breast cancer. The study showed that...
A trial reported in Journal of Clinical Oncology by John P. Crown, MD, of the Irish Cooperative Oncology Research Group, and colleagues assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to capecitabine (Xeloda) in patients with previously treated metastatic breast cancer who...
In a report published in Journal of the National Cancer Institute, Scarlett Lin Gomez, PhD, of the Cancer Prevention Institute of California, and colleagues detailed cancer incidence trends among Asian American populations from 1990 through 2008. The findings indicate a need for increased...
In a study reported in Journal of the National Cancer Institute, Paul Lochhead, MBChB,MRCP, of the Dana-Farber Cancer Institute and Harvard Medical School, and colleagues analyzed the association of microsatellite instability and BRAF status subgroups with survival in patients with colorectal...
Cisplatin plus fluorouracil (5-FU) induction chemotherapy has been compared with taxane (docetaxel or paclitaxel), cisplatin, and 5-FU in randomized trials in locoregionally advanced head and neck cancers. An updated individual patient data meta-analysis reported in the Journal of Clinical Oncology ...
In a study reported in Lancet Oncology, Timothy Key, PhD, of Oxford University, and colleagues in the Endogenous Hormones and Breast Cancer Collaborative Group analyzed data from seven prospective studies to determine associations between sex hormones and risk of breast cancer in premenopausal...
In a study reported in Journal of Clinical Oncology, Kelly-Anne Phillips, MD, of Peter MacCallum Cancer Centre and University of Melbourne, and colleagues analyzed the association of adjuvant tamoxifen use and risk of contralateral breast cancer among women carrying BRCA1 and BRCA2 mutations in the ...
Minimal data are available on outcomes of second allogeneic hematopoietic stem cell transplantation from unrelated donors after first hematopoietic stem cell transplantation in patients with hematologic relapse of acute leukemia. In a study reported in Journal of Clinical Oncology, Maximilian...
In a study reported in Journal of Clinical Oncology, David Margel, MD, PhD, of University of Toronto, and colleagues examined the effect of duration of antidiabetic medication exposure after prostate cancer diagnosis on all-cause and prostate cancer–specific mortality in men with diabetes....
In a phase II study (BREAK-2) reported in Journal of Clinical Oncology, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori Fondazione G. Pascale, and colleagues assessed the activity of the mutated BRAF kinase inhibitor dabrafenib (Tafinlar) in patients with BRAF-V600E/K mutant metastatic...
The contribution of purging of peripheral blood stem cells to outcome of autologous stem cell transplantation in high-risk neuroblastoma has not been defined. In a trial (COG A3973) reported in Lancet Oncology by Susan G. Kreissman, MD, of Duke University Medical Center, and colleagues, children...
In the SoFEA trial, reported in Lancet Oncology by Stephen R.D. Johnston, PhD, FRCP, of Royal Marsden NHS Foundation Trust, and colleagues, postmenopausal women with advanced hormone receptor–positive breast cancer that progressed on nonsteroidal aromatase inhibitors were treated with the...
In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...
In a report in Journal of Clinical Oncology, Sonali M. Smith, MD, of University of Chicago Hospitals, and colleagues analyzed outcomes in a large cohort of autologous or allogeneic hematopoietic cell transplantation recipients with the most common T-cell non-Hodgkin lymphoma histologies. Their ...
The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...
A number of initiatives have been implemented to encourage reduction of inappropriate use of imaging to stage incident prostate cancer. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by...
Ambient air pollution has been associated with lung cancer risk. In a study reported in Lancet Oncology by Ole Raaschou-Nielsen, PhD, of the Danish Cancer Society Research Center, and colleagues, lung cancer incidence in European countries was prospectively assessed according to several measures of ...
The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer, and the investigational endothelin receptor antagonist atrasentan has shown activity in prostate cancer. In the SWOG S0421 trial reported in Lancet Oncology by David I. Quinn, FRACP, of...
There is ongoing debate about the efficacy of erlotinib (Tarceva) in patients with advanced non–small cell lung cancer (NSCLC) whose tumors have wild-type EGFR. In the TAILOR trial, reported in Lancet Oncology by Marina Chiara Garassino, MD and colleagues, erlotinib was compared with standard ...
In a study reported in Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy, and colleagues evaluated survival outcomes in locally advanced cervical cancer patients with negative PET-CT imaging results who underwent laparoscopic para-aortic staging surgery before...
A number of different strategies for combining chemotherapy and radiation therapy have been evaluated in the effort to improve survival in patients with high-risk medulloblastoma. In a trial (POG 9031) reported in Journal of Clinical Oncology, Nancy J. Tarbell, MD, of Massachusetts General Hospital ...
The differential diagnosis of the most common peripheral T-cell lymphoma subtypes is difficult. In a phase III diagnostic accuracy study reported in Journal of Clinical Oncology, Pier Paolo Piccaluga, MD, PhD, of the University of Bologna, and colleagues in the European T-cell Lymphoma Study Group...
The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung cancer mortality compared with chest radiography in participants aged 55 to 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since...
In a trial (ALSYMPCA) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, United Kingdom, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and...
Decreased pregnancy rates and early menopause have been reported in female cancer survivors, although there is less information on infertility rates and reproductive interventions in these patients. In a study reported in Lancet Oncology, Sara E. Barton, MD, of Brigham and Women’s Hospital...
In an open-label phase III trial (ASPECT) reported in Lancet Oncology, Manfred Westphal, MD, of University Hospital Eppendorf in Hamburg, and colleagues assessed the effects of locally applied adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir after...
Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in Lancet Oncology, Weiva Sieh, PhD, of Stanford University and colleagues assessed the...
In a collaborative phase III trial of the North Central Cancer Treatment Group and Mayo Clinic reported in Journal of the National Cancer Institute by Debra L. Barton, RN, PhD, of the Mayo Clinic, and colleagues, patients with cancer-related fatigue were treated with Wisconsin ginseng (a common...
The RAPID trial compared accelerated partial-breast irradiation using three-dimensional (3D) conformal external-beam radiation therapy vs whole-breast irradiation in women with invasive or in situ breast cancer ≤ 3 cm. As reported by Ivo A. Olivotto, MD, FRCPC, of the British Columbia Cancer...
Maintenance therapy is associated with improved survival in non–small cell lung cancer (NSCLC), but few studies have compared active agents in this setting. In a phase III trial (AVAPERL trial) reported in Journal of Clinical Oncology by Fabrice Barlesi, MD, PhD, of Aix Marseille...
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...
Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices ...
The NCI-60 cell lines, which represent cancers of lung, colon, brain, ovary, breast, prostate, and kidney as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As...